Advocacy at a Glance STEVEN GROSSMAN 5/16/21 Advocacy at a Glance STEVEN GROSSMAN 5/16/21 Hill Day with Senate staff on May 25 and 26, with Alliance members invited to participate. Read More Analysis and Commentary STEVEN GROSSMAN 4/3/20 Analysis and Commentary STEVEN GROSSMAN 4/3/20 Advocating for a Responsibility-based "Ask" Read More Advocacy at a Glance STEVEN GROSSMAN 4/3/20 Advocacy at a Glance STEVEN GROSSMAN 4/3/20 Alliance Submits House/Senate Testimony on FY 21 Appropriations for FDA Read More Advocacy at a Glance STEVEN GROSSMAN 3/20/20 Advocacy at a Glance STEVEN GROSSMAN 3/20/20 Alliance Completes Hill Day with Conference Calls and Much Enthusiasm on Both Sides Read More Advocacy at a Glance STEVEN GROSSMAN 3/6/20 Advocacy at a Glance STEVEN GROSSMAN 3/6/20 Alliance Hill Day On March 18; You Don’t Have to Be an FDA Expert to Participate Read More Advocacy at a Glance STEVEN GROSSMAN 2/28/20 Advocacy at a Glance STEVEN GROSSMAN 2/28/20 Coronavirus Supplemental Likely to Be Considered Quickly Read More Advocacy at a Glance STEVEN GROSSMAN 3/29/19 Advocacy at a Glance STEVEN GROSSMAN 3/29/19 Commissioner Gottlieb Testifies Before the Senate Ag/FDA Appropriations Subcommittee Read More Advocacy at a Glance STEVEN GROSSMAN 2/22/19 Advocacy at a Glance STEVEN GROSSMAN 2/22/19 FY 20 Budget Release Dates Announced Read More STEVEN GROSSMAN 2/15/19 STEVEN GROSSMAN 2/15/19 Long Wait Is Over. FY 19 FDA Funding Will Be Set When the President Signs the Appropriations Bill Read More STEVEN GROSSMAN 2/8/19 STEVEN GROSSMAN 2/8/19 CR/Shutdown Countdown: One Week to Go Read More Advocacy at a Glance STEVEN GROSSMAN 4/21/18 Advocacy at a Glance STEVEN GROSSMAN 4/21/18 Alliance’s Hill Day on April 25. Please Join Us Read More Advocacy at a Glance STEVEN GROSSMAN 4/13/18 Advocacy at a Glance STEVEN GROSSMAN 4/13/18 Notes from the Alliance’s Meeting with CBER Director Peter Marks and more Read More Advocacy at a Glance STEVEN GROSSMAN 6/23/17 Advocacy at a Glance STEVEN GROSSMAN 6/23/17 CBO Score on Senate FDARA Bill Leads to Confusion About Unfunded Mandates and more Read More Advocacy at a Glance STEVEN GROSSMAN 5/26/17 Advocacy at a Glance STEVEN GROSSMAN 5/26/17 New FDA Commissioner Testifies and more Read More Advocacy at a Glance STEVEN GROSSMAN 5/19/17 Advocacy at a Glance STEVEN GROSSMAN 5/19/17 New FDA Commissioner Scott Gottlieb Read More Advocacy at a Glance STEVEN GROSSMAN 3/24/17 Advocacy at a Glance STEVEN GROSSMAN 3/24/17 President’s Budget Blueprint Puts FDA at Risk and more Read More Analysis and Commentary STEVEN GROSSMAN 3/4/16 Analysis and Commentary STEVEN GROSSMAN 3/4/16 Califf Debuts on Capitol Hill with Two Priorities Read More Advocacy at a Glance STEVEN GROSSMAN 3/4/16 Advocacy at a Glance STEVEN GROSSMAN 3/4/16 National Biomedical Research Act Introduced Read More Analysis and Commentary STEVEN GROSSMAN 2/27/16 Analysis and Commentary STEVEN GROSSMAN 2/27/16 "Everything is a high priority" for the FDA today Read More Advocacy at a Glance STEVEN GROSSMAN 2/27/16 Advocacy at a Glance STEVEN GROSSMAN 2/27/16 Details on FDA’s Request for FY 17 FSMA Appropriations and more Read More Older Posts
Advocacy at a Glance STEVEN GROSSMAN 5/16/21 Advocacy at a Glance STEVEN GROSSMAN 5/16/21 Hill Day with Senate staff on May 25 and 26, with Alliance members invited to participate. Read More
Analysis and Commentary STEVEN GROSSMAN 4/3/20 Analysis and Commentary STEVEN GROSSMAN 4/3/20 Advocating for a Responsibility-based "Ask" Read More
Advocacy at a Glance STEVEN GROSSMAN 4/3/20 Advocacy at a Glance STEVEN GROSSMAN 4/3/20 Alliance Submits House/Senate Testimony on FY 21 Appropriations for FDA Read More
Advocacy at a Glance STEVEN GROSSMAN 3/20/20 Advocacy at a Glance STEVEN GROSSMAN 3/20/20 Alliance Completes Hill Day with Conference Calls and Much Enthusiasm on Both Sides Read More
Advocacy at a Glance STEVEN GROSSMAN 3/6/20 Advocacy at a Glance STEVEN GROSSMAN 3/6/20 Alliance Hill Day On March 18; You Don’t Have to Be an FDA Expert to Participate Read More
Advocacy at a Glance STEVEN GROSSMAN 2/28/20 Advocacy at a Glance STEVEN GROSSMAN 2/28/20 Coronavirus Supplemental Likely to Be Considered Quickly Read More
Advocacy at a Glance STEVEN GROSSMAN 3/29/19 Advocacy at a Glance STEVEN GROSSMAN 3/29/19 Commissioner Gottlieb Testifies Before the Senate Ag/FDA Appropriations Subcommittee Read More
Advocacy at a Glance STEVEN GROSSMAN 2/22/19 Advocacy at a Glance STEVEN GROSSMAN 2/22/19 FY 20 Budget Release Dates Announced Read More
STEVEN GROSSMAN 2/15/19 STEVEN GROSSMAN 2/15/19 Long Wait Is Over. FY 19 FDA Funding Will Be Set When the President Signs the Appropriations Bill Read More
Advocacy at a Glance STEVEN GROSSMAN 4/21/18 Advocacy at a Glance STEVEN GROSSMAN 4/21/18 Alliance’s Hill Day on April 25. Please Join Us Read More
Advocacy at a Glance STEVEN GROSSMAN 4/13/18 Advocacy at a Glance STEVEN GROSSMAN 4/13/18 Notes from the Alliance’s Meeting with CBER Director Peter Marks and more Read More
Advocacy at a Glance STEVEN GROSSMAN 6/23/17 Advocacy at a Glance STEVEN GROSSMAN 6/23/17 CBO Score on Senate FDARA Bill Leads to Confusion About Unfunded Mandates and more Read More
Advocacy at a Glance STEVEN GROSSMAN 5/26/17 Advocacy at a Glance STEVEN GROSSMAN 5/26/17 New FDA Commissioner Testifies and more Read More
Advocacy at a Glance STEVEN GROSSMAN 5/19/17 Advocacy at a Glance STEVEN GROSSMAN 5/19/17 New FDA Commissioner Scott Gottlieb Read More
Advocacy at a Glance STEVEN GROSSMAN 3/24/17 Advocacy at a Glance STEVEN GROSSMAN 3/24/17 President’s Budget Blueprint Puts FDA at Risk and more Read More
Analysis and Commentary STEVEN GROSSMAN 3/4/16 Analysis and Commentary STEVEN GROSSMAN 3/4/16 Califf Debuts on Capitol Hill with Two Priorities Read More
Advocacy at a Glance STEVEN GROSSMAN 3/4/16 Advocacy at a Glance STEVEN GROSSMAN 3/4/16 National Biomedical Research Act Introduced Read More
Analysis and Commentary STEVEN GROSSMAN 2/27/16 Analysis and Commentary STEVEN GROSSMAN 2/27/16 "Everything is a high priority" for the FDA today Read More
Advocacy at a Glance STEVEN GROSSMAN 2/27/16 Advocacy at a Glance STEVEN GROSSMAN 2/27/16 Details on FDA’s Request for FY 17 FSMA Appropriations and more Read More
